Garry Neil, Avalo Therapeutics CEO
May 5, 2022 10:47 AM EDTUpdated May 6, 05:51 PM
People
Pharma

Ava­lo Ther­a­peu­tics to lay off 33% of staff amidst mar­ket strug­gles and pen­ny stock sta­tus

Tyler Patchen

News Reporter

Ava­lo Ther­a­peu­tics is con­tin­u­ing to hit bumps in its jour­ney as it is ex­e­cut­ing a work­force re­duc­tion to fo­cus more on its pipeline.

The Rockville …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times